Stock NANEXA NANEXA AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Nanexa AB

Equities

NANEXA

SE0007074166

Delayed Nasdaq Stockholm
Other stock markets
 07:04:53 2024-05-29 am EDT 		5-day change 1st Jan Change
1.05 SEK -4.55% Intraday chart for Nanexa AB +23.24% -14.63%
May. 15 Nanexa AB Elects Hanna Tilus as Members of the Board CI
May. 15 Nanexa AB Receives Approval for NEX-22 Clinical Study CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company appears to be poorly valued given its net asset value.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses

  • Low profitability weakens the company.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
NANEXA AB Stock Nanexa AB
-14.63% 14.15M -
CROSSJECT Stock Crossject
-58.75% 85.18M -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality
  1. Stock Market
  2. Equities
  3. NANEXA Stock
  4. Ratings Nanexa AB